Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

The SHARON trial is ongoing and will be expanding to include patients without a BRCA or PALB2 mutation, and General Oncology plans to continue evaluating outcomes and long-term follow-up in this ...

A team from the Faculty of Physics and the Center for Quantum Optical Technologies at the University of Warsaw has developed ...

Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaRecommendation based on LUNA 3 phase 3 study ...

NMIMS to roll out AI-led interviews with sentiment tracking, measuring facial expressions, tone, and confidence of MBA ...

AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar ...

The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who ...

A team from the Faculty of Physics and the Centre for Quantum Optical Technologies at the University of Warsaw has developed a new type of all-optical ...

A comprehensive peer-reviewed invited review published today in Psychedelics by Dr. Kenji Hashimoto and colleagues (Dr.

First OX40 Targeted Therapy Approval By 2030 Says Kuick Research In New Research StudyDelhi, Oct. 14, 2025 (GLOBE NEWSWIRE) - ...

Breakthrough from Princeton team reveals exotic quantum state that coherently blends many-body correlation and quantum ...